Hemostasis Techniques for Non-variceal Upper GI Hemorrhage: Beyond Injection and Cautery

B. Nulsen1,2,3,5 · D. M. Jensen1,2,3,4

Accepted: 5 April 2021 / Published online: 8 June 2021
© The Author(s) 2021

Introduction

Acute non-variceal upper GI hemorrhage (NVUGIH) is a common indication for hospitalization in the USA with a reported incidence of 66.7 cases per 100,000 [1]. Peptic ulcer disease, gastroduodenal erosions, Mallory–Weiss tears (MWT) and esophagitis are frequent causes of NVUGIH and account for more than 80% of cases. Other less common etiologies include Cameron ulcers, UGI cancers, angiodysplasia, polyps, gastric antral vascular ectasia (GAVE), and Dieulafoy’s lesions (DL).

Recurrent NVUGIH is common in high-risk patients and is associated with complications and increased mortality [2–9]. The current standard of care is to treat patients with severe NVUGIH with endoscopic therapy based on visual stigmata of recent hemorrhage [SRH] [2–4]. These standard treatments include thermocoagulation (argon plasma coagulation [APC], multipolar electrocautery [MPEC]) and through-the-scope hemoclips [HC], either alone or in combination with epinephrine pre-injection [3, 9]. For NVUGIH, the goals of endoscopic treatment are to control active bleeding and prevent rebleeding by obliterating arterial blood flow underneath the SRH [10, 11]. However, rebleeding still occurs in up to 26% of high-risk patients with major SRH in peptic ulcers despite these therapies based on visual
criteria [10]. Several promising techniques have emerged in the last decade which are important options for reducing rebleeding rates and improving clinical outcomes (Table 1). This review will present the scientific evidence for these novel strategies, including whether they result in definitive hemostasis, which is defined as successful endoscopic treatment of high-risk patients for control of active bleeding and prevention of rebleeding.

**Doppler Endoscopic Probe**

The Doppler endoscopic probe was first described in 1982 [12]. As a single-use endoscopic probe and device (DEP; Vascular Technology Inc, Nashua, NH), this is approved by the United States Food and Drug Administration (FDA). It does not provide direct hemostasis, but assists in lesion risk stratification by identifying underlying arterial blood flow, mapping its path, and guiding endoscopic hemostasis [10, 11]. This is especially useful in lesions with SRH and underlying arteries such as oozing bleeding, non-bleeding visible vessels and flat spots, whose characterization can be challenging and subjective compared to visual cues alone [11, 13]. In addition to risk stratification, DEP can also be used to confirm eradication of arterial blood flow after endoscopic therapy for definitive hemostasis in lesions with SRH [10, 11].

DEP is easy to use and to teach endoscopists how to apply [10, 11, 14]. The tip of the Doppler probe is lubricated and passed through the working channel of the diagnostic or therapeutic upper endoscope. It is then lightly applied to the SRH in a tangential orientation and then moved away from the SRH for 5–10 mm in a straight line [10, 11]. This is then repeated in four different quadrants to detect the direction of blood flow and location of the underlying vessel (Fig. 1) [10, 11]. While the use of Doppler has primarily been described in treating peptic ulcers, it can also be used for other focal non-variceal upper GI lesions with underlying arteries such as Dieulafoy’s lesions and Mallory–Weiss tears [10, 11, 15].

Advantages of the DEP system are its ability to guide risk stratification and validate risk of visual SRH, its low cost ($150–$200 USD), ease of use, and safety. Disadvantages include endoscopists needing to learn a new technique, possible variability among endoscopists in DEP signal interpretation, and nominal extra cost of disposable probes (Table 2).

Several cohort studies reported DEP as a promising tool for stratifying patients with focal lesions and SRH at high risk of rebleeding and improving rebleeding rates (Table 3). The outcomes reported in earlier studies are limited in current relevance by use of injection monotherapy (now regarded as less effective) and second look endoscopy (not routinely used and not recommended) [16–19]. However, a 2016 prospective cohort study examined the use of DEP in patients with severe peptic ulcer bleeding and reported that 27.4% of patients with major SRH (arterial spurting—Forrest 1A, non-bleeding visible vessel [NBVV]—Forrest 2A, and adherent clot—Forrest 2B) had residual arterial blood flow after modern, standard of care visually guided endoscopic treatment (MPEC or HC) [11]. The investigators additionally identified arterial blood flow underlying pigmented spots (Forrest 2C) in 40.5% of ulcer patients, which typically are not treated according to current guidelines [3, 9]. They later reported that rebleeding occurred in 20% of chronic ulcers with flat spots in patients treated medically [10]. The authors also concluded that DEP was more accurate than SRH alone to risk stratify ulcers for rebleeding at baseline and was useful as a guide for definitive endoscopic hemostasis of bleeding ulcers (Table 2).

A recent randomized clinical trial (RCT) supported the use of DEP in NVUGIH to improve clinical outcomes. This study compared standard visually guided therapy to DEP-guided treatment in 148 patients with severe NVUGIH (84.5% peptic ulcers, 12.8% DL and 2.7% bleeding MWT) [10]. The investigators reported a significantly lower rate of 30-day rebleeding among patients in the Doppler group (26.3% vs. 11.1%; p = 0.021) with a number needed to treat [NNT] of 7. By Kaplan–Meier analysis, there was a significant difference in time to lesion rebleeding (p = 0.017). There were also arithmetic lower rates of surgery, death, major complications, transfusions, and hospital days in the DEP group. This RCT also importantly identified that 89% of patients with residual post-treatment arterial blood flow ultimately rebled, as compared to 0% among patients with a positive post-treatment DEP that was further treated until negative (89.9% vs. 0.0%; p < 0.001). This finding corroborated earlier cohort studies which reported increased risk of rebleeding in patients with persistently positive post-treatment arterial blood flow in peptic ulcers [19, 20]. This study was included in a recent meta-analysis which found significantly lower rates of rebleeding [OR 0.13 (95% CI 0.04–0.44); P = 0.001], need for surgery [OR 0.05 (95% CI 0.01–0.24); P < 0.001], and bleeding associated mortality [OR 0.19 (95% CI 0.05–0.81); I = 0.00; P = 0.025] among 284 patients randomized to treatment with DEP versus conventional management [21].

As a corollary, persistent arterial blood flow under SRH usually causes rebleeding in high-risk patients with focal NVUGIH [10, 11]. These results emphasize that arterial blood flow underneath the SRH in focal lesions (such as ulcers and DL) is a major risk factor for lesion rebleeding. Obliteration of arterial blood flow underneath SRH prevents rebleeding [10, 11].

In addition to its promising effect on clinical outcomes, DEP has an excellent safety profile. In a meta-analysis of 526 patients enrolled in ten studies, no patients experienced any DEP-related adverse events [21]. DEP has also been
shown to be cost effective when compared to conventional, visually guided therapy in acute peptic ulcer bleeding (PUB) in several different cost-analyses [22–24]. As one example, when used to direct treatment of ulcers with flat pigmented spots (Forrest 2C), DEP-guided therapy was more effective and less expensive than visually guided hemoclips over a 30 day time horizon [23].

### OTSC

The large, over-the-scope clip (OTSC; Ovesco Endoscopy, Tuebingen, Germany) is a novel endoscopic clipping device that was first reported in 2007 in a case series which described its successful use in repair of gastrointestinal perforations and treatment of GI bleeding [25]. The OTSC applicator cap attaches to the tip of the endoscope similar to a band ligation device. There are multiple sizes ranging from 11 to 14 mm (depending on the size of endoscope that is being used) and also types of teeth (blunt and several sharp versions for various applications) (Fig. 2). OTSC was later described as a treatment for NVUGIH in retrospective and cohort studies and meta-analyses, with high rates of technical success and rebleeding rates ranging from 0 to 35% [26–34]. In addition to their retrospective design, these studies are limited by heterogeneity in terms of bleeding etiology, location, and therapeutic timing.

Advantages of OTSC include its ability to embed in and treat large or fibrotic ulcers due to its size and significant compression force; relatively infrequent complications; and modest cost ($400–$450 USD) (Fig. 3). Disadvantages include the need to remove the endoscope, attach the applicator cap (often to a smaller endoscope), and reintubate the patient prior to treatment; difficulty passing through luminal...
| Hemostasis modality                        | Advantages                                                                 | Disadvantages                                                                 |
|-------------------------------------------|----------------------------------------------------------------------------|-------------------------------------------------------------------------------|
| Doppler endoscopic probe (DEP)            | Easy to learn and apply                                                    | Auditory interpretation of Doppler signal                                      |
|                                           | Does not require withdrawal of endoscope prior to use                      | Does not provide direct hemostasis                                             |
|                                           | No complications                                                          |                                                                                |
|                                           | Inexpensive                                                               |                                                                                |
| Over-the-scope-clip (OTSC)                | Ability to grasp a large volume of tissue                                  | Requires endoscope withdrawal to load device                                  |
|                                           | Ability to grasp and embed in fibrotic tissue                              | Challenging to intubate esophagus or traverse luminal stenosis                |
|                                           | Infrequent complications                                                  | Difficult to position and deploy onto tangential positions                    |
| TC-325 (Hemospray)                        | Does not require focal/targeted treatment                                  | Technical complications (occlusion of spray catheter or instrument channel)    |
|                                           | Non-thermal and non-traumatic                                              | Sloughs off quickly (<24 h)                                                   |
|                                           | Ability to treat diffuse lesions (e.g., tumors)                            | Does not obliterate underlying arterial or venous blood flow                   |
|                                           | Relative ease of deployment                                                | Reduced lesion visualization after use                                          |
|                                           |                                                                           | Expensive                                                                     |

Table 3

| Author   | Study design and size (N) | Study population (Forrest I-III) | Treatment | Rebleeding rates | Important secondary outcomes |
|----------|--------------------------|----------------------------------|------------|------------------|------------------------------|
| Jaspersen [52] | Prospective N = 11 | Ulcers Injection^ | DEP+: 9% (1/11) | Second look endoscopy: 0% residual DEP+ |
| Kohler [16] | Cohort N = 140 | Ulcers Injection^ | DEP+: 9% (7/78) | Second look endoscopy: 21% residual DEP+ |
| Kohler [18] | RCT N = 100 | Ulcers Injection^ | SRH: 14% | Surgery: SRH 5% vs. DEP 0%* |
| Wong [20] | Observational N = 55 | PUD Injection^ ± Thermal | Post-treatment DEP(−): | Post-treatment DEP: |
| Van Leerdam [19] | Cohort N = 50 | Ulcers Injection^ | DEP+: 12% (5/41) | Post-treatment DEP: |
|            | Randomized N = 30 | Ulcers Injection^ | DEP+: 22% (2/9) | Positive: 100% |
|            |                |                   | DEP+: 0% | Negative: 11%* |
|            |                |                   | DEP+: 7.1% | Negative: 4% (1/27) rebleed* |
| Jakobs [53] | Prospective N = 9 | Ulcers Injection^ | 20% (4/20) | Second look endoscopy: Surgery: Post-treatment DEP Neg 10% (2/20) |
| Jensen [11] | Observational N = 162 | Ulcers Injection^ | Forrest 1A: 29% | Post-treatment Residual DEP+: Forrest 1A, 2A, 2B: 27.4% Forrest 1B: 0* |
| Jensen [10] | RCT N = 148 | Ulcers Injection^ | DEP: 11.1% (8/72) | Post-treatment DEP: |
|            |                |                   | Standard: 26.3 (20/76)* | Positive: 88.9% rebleed |
|            |                |                   |                | Negative: 0% rebleed* |

*Indicates significant p value (<0.05)

^Injection of dilute epinephrine (1:10,000 or 1:20,000) and/or sclerosant
For NVUGIH, rates of persistent arterial blood flow and hemorrhage than standard endoscopic hemostasis techniques. OTSC would be more effective at treating NVUGIH with significant compression force, we hypothesized that OTSC would treat fibrotic tissue also through-the-scope hemoclips and also fibrotic tissue with underlying arterial blood flow by DEP.

The OTSC was also reported in an earlier trial (“STING”) that randomized 66 patients with recurrent peptic ulcer bleeding to either OTSC or standard therapy with epinephrine pre-treatment of active bleeding or adherent clots) with subsequent management by physicians blinded to the endoscopic treatment. We reported a significantly lower rate of 30-day rebleeding in the OTSC arm when compared to the standard therapy arm (28.6% vs. 4%; p = 0.017) with a NNT of 4. All of the rebleeds occurred in patients with major stigmata of recent hemorrhage (active spurting or pulsatile arterial bleeding, NBVV, or adherent clot) and no patient with lesser stigmata (oozing or flat spot with positive arterial Doppler signal) rebled. Severe medical complications and post-treatment RBC transfusions were also significantly less frequent in the OTSC group when compared to the standard group [36].

The rates of residual blood flow after standard visually guided endoscopic hemostasis of major SRH were significantly higher than OTSC-treated lesions (24% vs 5%) and the rebleeding rates were also significantly higher (26% vs. 5%). As with DEP-guided hemostasis, successful obliteration of arterial blood flow with OTSC leads to definitive hemostasis of severe focal NVUGIH [10, 11, 35].

Prospective randomized reports on the use of OTSC are currently limited to two RCTs (Table 4). A recent study by the CURE Hemostasis group is the only prospective, randomized study describing the use of OTSC in the first line setting for treatment of severe upper GI hemorrhage [36]. This two center trial randomized 53 patients with either peptic ulcer disease (91%) or DL (9%) to treatment with OTSC or standard therapy (MPEC and/or HC, ± epinephrine pre-treatment of active bleeding or adherent clots) with subsequent management by physicians blinded to the endoscopic treatment. We reported a significantly lower rate of 30-day rebleeding in the OTSC arm when compared to the standard therapy arm (28.6% vs. 4%; p = 0.017) with a NNT of 4. All of the rebleeds occurred in patients with major stigmata of recent hemorrhage (active spurting or pulsatile arterial bleeding, NBVV, or adherent clot) and no patient with lesser stigmata (oozing or flat spot with positive arterial Doppler signal) rebled. Severe medical complications and post-treatment RBC transfusions were also significantly less frequent in the OTSC group when compared to the standard group [36].

The OTSC was also reported in an earlier trial (“STING”) that randomized 66 patients with recurrent peptic ulcer bleeding to either OTSC or standard therapy with epinephrine injection and/or through-the-scope clips as treatment of peptic ulcer bleeds (PUBs) [37]. There were major methodologic differences from the CURE RCT because crossover was the design and patient care physicians were not blinded to the endoscopic treatments. The authors reported

### Table 4: Prospective studies of the over-the-scope clip (OTSC) in Non-variceal Upper GI Hemorrhage (NVUGIH)

| Author       | Study design and size (N) | Study population | Treatments | Rebleeding rates | Significant secondary outcomes |
|--------------|---------------------------|------------------|------------|-----------------|------------------------------|
| Schmidt [37] | RCT (N = 66) Not blinded 19 center | Recurrent Ulcer Bleeding | OTSC—33 Standard—33 (cross-over) | “Further bleeding” @ 7 days OTSC—15.2 Standard—57.6 | Cumulative 30-day “further bleeding” in OTSC (including 14 crossover): 10.6% |
| Jensen [36]  | RCT (N = 53) Blinded 2 centers | Initial treatment of Ulcers & Dieulafoy’s Lesions with major or lesser SRH | OTSC—25 Standard—28 (no cross-over) | 30-day rebleeding: OTSC: 28.6% Standard: 4% | Medical complications: OTSC (0%) vs. Standard (14.3%)* Post-treatment transfusion: OTSC (0.68) vs. Standard (0.04)* |

SRH is stigmata of recent hemorrhage. Major SRH are active arterial bleeding (Forrest IA), non-bleeding visible vessel (FIHA), or adherent clot (FIIB). Lesser SRH are oozing bleeding (FIA) or flat spot (FIIC) with underlying arterial blood flow by DEP.
a composite primary outcome of “further bleeding,” which included persistent bleeding despite treatment or rebleeding within 7 days. Further bleeding occurred in 57.6% of patients in the standard therapy group compared to 15.2% in the OTSC group (p = 0.001). This was driven by rates of persistent bleeding despite initial re-treatment (42.4% vs. 6.0%; p = 0.001) more so than 7-day rebleeding (16.1% vs 9.1%; p = 0.468). A cost analysis based on the STING study results concluded that OTSC was cost effective in recurrent peptic ulcer bleeding, despite the increased cost of these clips [38].

**TC-325**

TC-325 (Hemospray, Cook Medical, Winston-Salem, North Carolina, USA) is a biologically inert powder that creates a mechanical barrier over bleeding sites when it comes in contact with aqueous solution. Its clinical GI use was first reported in a 2011 case series of 20 patients with peptic ulcer bleeding and it was approved by the US FDA for endoscopic hemostasis in 2018 [39]. Several international consensus statements support the use of TC-325 as temporizing therapy when experienced endoscopists are not available or other endoscopic modalities that are applied do not control active bleeding [6, 9].

The advantages of the TC-325 treatment are that it can be easily sprayed from a distance onto bleeding areas to slow or stop active bleeding. (Fig. 4) It does not require the level of expertise that is needed to identify, prepare, and effectively treat focal bleeding for definitive hemostasis with standard visually guided techniques of bleeding sites. TC-325 can also be used to treat diffuse mucosal or neoplasia bleeding. The major limitations of TC-325 as a topical agent are 1) that is sloughs off after a short time (usually < 24 h), 2) it does not prevent rebleeding nor result in definitive hemostasis of focal lesions with NVUGIH because arterial blood flow underneath SRH is not obliterated, 3) additional endoscopic treatments to prevent rebleeding by obliterating arterial blood flow are required to achieve permanent hemostasis and 4) each treatment is expensive ($2500 USD) (Table 2).

Several technical tips are important to remember when utilizing TC-325. First, it is important to take proactive measures to avoid catheter occlusion. This includes flushing the accessory channel with air prior to passing the catheter & avoiding direct contact between the catheter tip and pooled blood, mucosa, and the actively bleeding lesion. The endoscopist should avoid aspirating blood while the catheter

---

**Table 5** Prospective studies of TC-325 (hemospray) in non-variceal upper GI hemorrhage (NVUGIH)

| Author          | Study design and size | Study population | Treatment                  | Immediate hemostasis | Rebleeding rates |
|-----------------|-----------------------|------------------|----------------------------|----------------------|------------------|
| Pittayanon [54] | Prospective Cohort (N = 10) | Tumors           | N = 10                     | –                    | Hemospray: 10%   |
|                 |                       |                  | Hemospray—10               |                      | Historical Control: 30% |
|                 |                       |                  | Historical Control—10      |                      |                  |
| Haddara [55]   | Prospective Observational (N = 202) | PUD (31%) Tumors (30%) Post-endoscopic (17%) | All Hemospray       | Hemospray: 96.5% | Overall: 33.5% |
|                 |                       |                  |                            |                      | PUD: 38%         |
|                 |                       |                  |                            |                      | Tumors: 25%      |
|                 |                       |                  |                            |                      | Post-endoscopic: 33.5% |
| Kwek [48]      | RCT (N = 19)          | PUD              | N = 19                     | Hemospray: 90%       | Hemospray: 33%   |
|                 |                       |                  | Hemospray—9 Conventional—10 | Hemoclip: 100%       | Hemoclip: 10%    |
| Baracat [42]   | RCT (N = 39)          | Active Bleeding  | N = 39                     | Hemospray: 95%       | Hemospray: 27.8% |
|                 |                       | PUD (44%) “Other” (16%) Malignancy (13%) Mallory-Weiss (8%) | Hemospray—19 Hemoclip—20 | Hemoclip: 90%       | Hemoclip: 15.8%  |
| Chen [43]      | RCT (N = 20)          | Tumors           | N = 20                     | Hemospray: 90%       | Hemospray: 20%   |
|                 |                       |                  | Hemospray—10 Conventional—10* | Hemoclip: 40%       | Hemoclip: 60%    |
| Alzoubaidi [56]| Prospective Observational (N = 314) | PUD (53%) Tumors (16%) Post-endoscopic (16%) | All hemospray       | Hemospray: 89.5% | Overall: 10.3% |
|                 |                       |                  |                            |                      | Monotherapy: 7.3% |
|                 |                       |                  |                            |                      | Combination: 9.6% |
| Hussein [50]   | Prospective Observational (N = 202) | PUD              | All Hemospray              | Hemospray: 88%       | Overall: 17%     |
| Lau [41]       | RCT (N = 224)         | PUD (58%) Tumors (14.3%) | Hemospray—111 Standard—113 | Hemospray: 2.7%      | Hemospray: 8.1%  |
|                 |                       |                  | Standard: 9.7%             |                      | Hemoclip: 8.8%   |

---

(Disclaimer: This text is a natural representation of the document content as per the instructions provided.)
is in the accessory channel because this can lead to occlusion. Second, the endoscopist should maintain the catheter tip at least 1-2 cm away from the SRH in order to allow adequate visualization of the lesion without blood touching the device. Finally, the endoscopist should “paint” the actively bleeding lesion with several layers of TC-325. Multiple applications can facilitate hemostasis if the first layer of powder is unsuccessful [40].

Prospective data regarding the use of TC-325 in NVUGIH are limited at this time to four prospective randomized trials and observational studies (Table 5). Only published as an abstract, the largest RCT to date included 224 patients with active non-variceal bleeding that were randomly assigned to TC-325 or standard treatment [41]. The most prevalent etiologies of bleeding were peptic ulcer disease (58%) and upper GI tumors (14.3%). Oozing bleeding (Forrest 1B) was much more prevalent than active arterial bleeding (Forrest 1A). In intention-to-treat analysis, the authors reported 30-day rebleeding-free probabilities of 89.8% in the TC-325 group and 81.1% in the standard treatment group (p=0.612). The authors concluded that TC-325 was not inferior to standard endoscopic control of active bleeding from various non-variceal UGI lesions.

Several smaller randomized studies also compared TC-325 to standard endoscopic treatments. Bacarat et al randomized 39 patients with active bleeding (84% oozing, 16% spurting) to first line treatment with TC-325 or standard hemoclips [42]. Peptic ulcer disease was the cause of bleeding in 44% of patients and other lesions included malignancy (13%), post-sphincterotomy bleeding (10%), Mallory-Weiss tear (8%) and Dieulafoy’s lesion (5%). There was no difference between the TC-325 and hemoclip group in terms of primary hemostasis (94.9% vs 90%; p = 0.487) and there was a nonsignificant trend toward increased rebleeding in the TC-325 group (27.9% vs. 15.8%; p = 0.572) at 1 week. There were no differences between the groups in rates of surgery, death, RBC transfusion or length of stay. Of the four patients with active bleeding from gastric tumors, none experienced rebleeding.

Another RCT examined the role of TC-325 in the management of tumor bleeding. The authors randomized 20 patients with acute bleeding from malignant tumors to either TC-325 or standard of care (thermal and/or injection therapies) [43]. Seventeen patients had bleeding in the upper GI tract. Immediate hemostasis was achieved in 90%

**Table 6** Overall rebleeding rates in PUBs from prospective trials

| Hemostasis modality         | Major stigmata (Forrest 1A, 2A, 2B)* (%) | Lesser stigmata (Forrest 1B, 2C)^ (%) |
|-----------------------------|------------------------------------------|---------------------------------------|
| Doppler endoscopic probe (DEP) | 15.4                                      | 1.1                                   |
| Over-the-scope-clip (OTSC)  | 9.4                                       | 11.5                                  |
| TC-325 (Hemospray)          | 23.6                                      | 17.1                                  |

*Major SRH are Forrest 1A (active arterial bleeding), Forrest 2A (non-bleeding visible vessel), Forrest 2B (adherent clot)

^Lesser SRG are Forrest 1B (oozing bleeding) or Forrest 2C (flat spot with underlying arterial blood flow by DEP)
of patients treated with TC-325 and 40% in the standard care arm \( (p = 0.057) \). Rebleeding at 30 days occurred in 20% and 60% in the TC-325 and standard care arms, respectively \( (p = \text{NS}) \). The results of this study were included in a recent meta-analysis (2 RCT, 2 prospective observational) which reported an overall tumor rebleeding rate of 21.9% \[44\]. This rate compares favorably to prior studies of other endoscopic modalities which found rates of immediate hemostasis as low as 40% and rebleeding in up to 30% \[45, 46\]. However, rebleeding of UGI and colon lesions with TC-325 as primary treatment remains high \[47\]. Such significant rebleeding requires definitive treatment with other endoscopic, angiographic, or surgical modalities.

A final prospective study used TC-325 in the treatment of high-risk peptic ulcers. The investigators randomized 20 patients with high-risk peptic ulcers (Forrest 1A, 2A, 2B) to standard treatment or TC-325 \[48\]. There was a nonsignificant trend towards increased rebleeding during second look endoscopy among those treated with TC-325 (33% vs. 10%; \( p = 0.582 \)).

Other case series reported rebleeding rates of 10–19% when TC-325 was used as monotherapy for peptic ulcer bleeding (PUB) \[39, 49\]. A recent registry analysis including more than 200 patients with actively bleeding ulcers reported initial hemostasis in 88% and rebleeding in 17% of patients \[50\]. At this time, the available data suggests that TC-325 is best used in cases of either active bleeding that cannot be controlled by the endoscopist using standard therapies or in diffuse tumor bleeding, which is not amenable to standard thermal or mechanical treatments. For patients with active arterial bleeding from PUBs, DLs or other focal NVUGI lesions, as opposed to oozing bleeding, TC-325 appears to be only a temporizing measure because it does not obliterate underlying arterial blood flow in focal lesions such as peptic ulcers or Dieulafoy’s lesions \[10, 11, 47\]. Definitive hemostasis by experienced endoscopists is required to prevent rebleeding in such patients.

**Conclusion**

Severe non-variceal upper GI bleeding from focal lesions such as PUBs and DLs remains a common clinical problem. Rebleeding is common when major SRH are treated with standard, visually guided hemoclipping or thermal coagulation \[10, 11, 15, 36\]. Doppler endoscopic probe and over-the-scope clip are promising new techniques that can decrease rebleeding rates, especially in high-risk patients.
TC-325 appears to be useful as a temporizing measure for continued bleeding of NVUGIH when standard hemostasis fails or is not available by skilled endoscopists or for palliation of diffuse tumor bleeding until more definitive treatments can be administered. Residual arterial blood flow in focal NVUGIH after standard hemostasis or TC-325 is a major risk factor for recurrent bleeding. Additional randomized, controlled trials are warranted to better define the respective roles of these new endoscopic treatments in the management of severe bleeding and whether these are cost effective. Finally, didactic and hands-on training sessions are needed and highly recommended to teach trainees and clinicians when and how to utilize these new hemostasis techniques [36, 51].

Summary

- Doppler endoscopic ultrasound (DEP), over-the-scope clip (OTSC), and TC-325 are promising new techniques for managing non-variceal upper-GI hemorrhage.
- DEP is easy to use and assists in lesion risk stratification and targeted obliteration of SRH of focal NVUGI lesions with underlying arterial blood flow.
- OTSC is useful for treating large or fibrotic ulcers to reduce rebleeding when compared to standard therapy, but training of endoscopists is needed.
- TC-325 is useful for treating diffuse bleeding of tumors and achieving initial hemostasis of active bleeding when standard hemostasis fails. However, underlying arterial blood flow is not obliterated by this topical technique and rebleeding of NVUGIH is common.
- Additional randomized clinical trial data is needed to better understand the clinical role for these novel endoscopic therapies.
- Didactic instruction about the indications and limitations of these new techniques and hands-on training are also recommended for both GI trainees and GI clinicians prior to application in emergency EGDs.

Funding Dr. Jensen and the CURE GI Hemostasis Research Unit studies were funded by NIH: NIDDK P30DK04301 CURE-DDRC (Human Studies Core), VA Clinical Merit Review Grants (CLIN-013-07F and 5I01CX001403) and the ASGE Research Foundation.

Compliance with Ethical Standards

Conflict of interest The authors declare that they have no conflict of interest.

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.

References

1. Wuerth BA, Rockey DC. Changing epidemiology of upper gastrointestinal hemorrhage in the last decade: a nationwide analysis. *Dig Dis Sci* 2018;63:1286–1293.
2. Barkun AN, Bardou M, Kuipers EJ, Sung J, Hunt RH, Martel M et al. International consensus recommendations on the management of patients with nonvariceal upper gastrointestinal bleeding. *Ann Intern Med* 2010;152:101–113.
3. Laine L, Jensen DM. Management of patients with ulcer bleeding. *Am J Gastroenterol* 2012;107:345–360.
4. Gralnek IM, Dumonceau J-M, Kuipers EJ, Lanas A, Sanders DS, Kurien M et al. Diagnosis and management of nonvariceal upper gastrointestinal bleeding. *Ann Intern Med* 2015;152:101–113.
5. Camus M, Jensen DM, Kovacs TO, Jensen ME, Markovic D, Gornbein J. Independent risk factors of 30-day outcomes in 1264 patients with peptic ulcer bleeding in the USA: large ulcers do worse. *Aliment Pharmacol Ther* 2016;43:1080–1089.
6. Sung JJ, Chiu PW, Chan FKL, Lau JY, Goh K-L, Ho LH et al. Asia-Pacific working group consensus on non-variceal upper gastrointestinal bleeding: an update 2018. Gut 2018;67:1757–1768.

7. Chiu PWY, Ng EKW, Cheung FKY, Chan FKL, Leung WK, Wu JCY et al. Predicting mortality in patients with bleeding peptic ulcers after therapeutic endoscopy. Clin Gastroenterol Hepatol 2009;7:311–316.

8. Marmo R, Koch M, Cipolletta L, Bianco MA, Grossi E, Rottoni G et al. Predicting mortality in patients with in-hospital non-variceal upper GI bleeding: a prospective, multicenter database study. Gastrointest Endosc 2014;79:741–749.

9. Barkun AN, Almadi M, Kuipers EJ, Laine L, Sung J, Tse F et al. Management of nonvariceal upper gastrointestinal bleeding: guideline recommendations from the international consensus group. Ann Intern Med 2019;171:805–822.

10. Jensen DM, Kovacs TOG, Ohning GV, Ghassemi K, Machicado GA, Dulai GS et al. Doppler endoscopic probe monitoring of blood flow improves risk stratification and outcomes of patients with severe nonvariceal upper gastrointestinal hemorrhage. Gastroenterology 2017;152:1310–1318.

11. Jensen DM, Ohning GV, Kovacs TOG, Ghassemi KA, Jutahba R, Dulai GS et al. Doppler endoscopic probe as a guide to risk stratification and definitive hemostasis of peptic ulcer bleeding. Gastrointest Endosc 2016;83:129–136.

12. Beckly DE, Casebow MP, Pettengell KE. The use of a Doppler ultrasound probe for localising arterial blood flow during upper gastrointestinal endoscopy. Endoscopy 1982;14:146–147.

13. Lau JY, Sung JJ, Chan AC, Lai GW, Lau JT, Ng EK et al. Stigmata of hemorrhage in bleeding peptic ulcers: an interobserver agreement study among international experts. Gastrointest Endosc 1997;46:33–36.

14. Wong RCK. Endoscopic Doppler US probe for acute peptic ulcer hemorrhage. Gastrointest Endosc 2004;60:804–812.

15. Nulsen B, Jensen DM, Kovacs TOG, Ghassemi KA, Kaneshiro M, Dulai DS et al. Outcomes in severe upper GI hemorrhage from Dieulafoy’s Lesion with monitoring of arterial blood flow. Dig Dis Sci 2020. https://doi.org/10.1007/s10620-020-06679-4

16. Kohler B, Rieman JF. Does Doppler ultrasound improve theosis of acute ulcer bleeding? Hepatogastroenterology 1994;41:51–53.

17. Fullarton GM, Murray WR. Prediction of rebleeding in peptic ulcers by visual stigmata and endoscopic Doppler ultrasound criteria. Endoscopy 1990;22:68–71.

18. Kohler B, Maier M, Benz C, Riemann JF. Acute ulcer bleeding. A prospective randomized trial to compare Doppler and Forrest classifications in endoscopic diagnosis and therapy. Dig Dis Sci 1997;42:1370–1374.

19. van Leerdam ME, Rauws EAJ, Geraedts AAM, Tijssen JGP, Tytgat GNJ. The role of endoscopic Doppler US in patients with peptic ulcer bleeding. Gastrointest Endosc 2003;58:677–684.

20. Wong RC, Chak A, Kobayashi K, Isenberg GA, Dulai GS, Carrol Locke DL et al. Role of Doppler US in acute peptic ulcer hemorrhage: can it predict failure of endoscopic therapy? Gastrointest Endosc 2000;52:315–321.

21. McCarthy TR, Sharma P, Jirapinyo P, Saltzman JR, Jensen DM, Thompson CC. Use of Doppler endoscopic probe for peptic ulcer disease associated bleeding: a systematic review and meta-analysis. Gastroenterology 2020;158:S9–S582.

22. Chen VK, Wong RCK. Endoscopic Doppler ultrasound versus endoscopic stigmata-directed management of acute peptic ulcer hemorrhage: a multimodal cost analysis. Dig Dis Sci 2007;52:149–160.

23. Yu JX, Russell WA, Soetinko RM, Jensen DM. Cost effectiveness of doppler endoscopic probe guided therapy of hemorrhage from peptic ulcers with flat pigmented spots. Gastrointest Endosc 2020;91:49.
Hemospray in achieving hemostasis in patients with acute peptic ulcer bleeding. Endoscopy 2011;43:291–295.

40. Barkun A. ASGE Tech Talks—gastrointestinal bleed management using hemospray endoscopic hemostat. Uploaded by ASGE Physician Education Videos, 16 Oct 2018. www.youtube.com/watch?v=_qaOZiJeQp0.

41. Lau JY, Pittayanon R, Kwek K, Tang RS, Chan H, Rerknimitr R et al. An non-inferiority randomized controlled trial to compare hemostatic powder Tc325 and standard therapy in bleeding from nonvariceal upper gastrointestinal causes. Gastrointest Endosc 2020;91:14.

42. Baracat FI, de Moura DTH, Brunaldi VO, Tranquillini CV, Baracat R, Sakai P et al. Randomized controlled trial of hemospray versus endoscopic clipping for non-variceal upper gastrointestinal bleeding. Surg Endosc 2020;34:317–324.

43. Chen Y-I, Wyse J, Lu Y, Martel M, Barkun AN. TC-325 hemostatic powder versus current standard of care in managing malignant GI bleeding: a pilot randomized clinical trial. Gastrointest Endosc 2020;91:321–328.

44. Chahal D, Tandon P, Jogendran M, Zhao B, Donnellan F. Hemospray for gastrointestinal bleeding: a meta-analysis. Gastrointest Endosc 2020;91:AB281.

45. Loftus EV, Alexander GL, Ahlquist DA, Balm RK. Endoscopic treatment of major bleeding from advanced gastroduodenal malignant lesions. Mayo Clin Proc 1994;69:736–740.

46. Giday S, Van Alstine W, Van Vleet J, Ducharme R, Brandner E, Florea M et al. Safety analysis of a hemostatic powder in a porcine model of acute severe gastric bleeding. Dig Dis Sci 2013;58:3422–3428.

47. Chahal D, Lee JGH, Ali-Mohamad N, Donnellan F. High rate of rebleeding after application of hemospray for upper and lower gastrointestinal bleeds. Dig Liver Dis 2020;52:768–772.

48. Kwek BEA, Ang TL, Ong PLJ, Tan YLJ, Ang SWD, Law NM et al. TC-325 versus the conventional combined technique for endoscopic treatment of peptic ulcers with high-risk bleeding stigmata: a randomized pilot study. J Dig Dis 2017;18:323–329.

49. Smith LA, Stanley AJ, Bergman JJ, Kiesslich R, Hoffman A, Tjwa ET et al. Hemospray application in nonvariceal upper gastrointestinal bleeding: results of the Survey to Evaluate the Application of Hemospray in the Luminal Tract. J Clin Gastroenterol 2014;48:e89-92.

50. Hussein M, Alzoubaidi D, Fraile-López M, Weaver M, Ortiz-Fernández-Sordo J, Bassett P et al. Hemostatic spray powder TC-325 in the primary endoscopic treatment of peptic ulcer related bleeding: multicentre international registry. Endoscopy 2021;53(1):36–43. https://doi.org/10.1055/a-1186-5360.

51. Dunkin BJ, Matthes K, Jensen DM. GI Hemostasis. In: Cohen J, ed. Oxford: Blackwell Publishing Ltd.; 2011:170–187.

52. Jaspersen D, Körner T, Wzatek J, Schorr W, Gaster CB, Hammar CH. Endoscopic Doppler sonography in gastroduodenal ulcer bleeding. Clin Investig 1992;70:705.

53. Jakobs R, Zoepf T, Schilling D, Siegel EG, Riemann JF. Endoscopic Doppler ultrasound after injection therapy for peptic ulcer hemorrhage. Hepatogastroenterology 2004;51:1206–1209.

54. Pittayanon R, Prueksapanich P, Rerknimitr R. The efficacy of Hemospray in patients with upper gastrointestinal bleeding from tumor. Endosc Int Open 2016;4:E933–E936.

55. Haddara S, Jacques J, Lecleire S, Branche J, Leblanc S, Le Baleur Y et al. A novel hemostatic powder for upper gastrointestinal bleeding: a multicenter study (the “GRAPHE” registry). Endoscopy 2016;48:1084–1095.

56. Alzoubaidi D, Hussein M, Rusu R, Napier D, Dixon S, Rey JW et al. Outcomes from an international multicenter registry of patients with acute gastrointestinal bleeding undergoing endoscopic treatment with Hemospray. Dig Endosc 2020;32(1):96–105. https://doi.org/10.1111/den.13502.

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Authors and Affiliations

B. Nulsen1,2,3,5 · D. M. Jensen1,2,3,4

1 CURE Digestive Diseases Core Research Center and CURE GI Hemostasis Research Unit, Los Angeles, CA, USA
2 David Geffen School of Medicine, Los Angeles, CA, USA
3 Vatche and Tamar Manoukian Division of Digestive Diseases and Department of Medicine, Los Angeles, CA, USA
4 Department of Medicine and GI Division, West Los Angeles Veterans Administration Medical Center, Los Angeles, CA, USA
5 UCLA Santa Monica Digestive Diseases, 1223 16th Street, Suite 3011, Santa Monica, CA 90404, USA